Riluzole, a drug used to slow down the progress of amyotrophic lateral sclerosis (ALS), will be tested in people with mild Alzheimer's disease. Cognitive functional changes and specific imaging biomarkers will be evaluated.
|Min Age||Max Age||Gender||Healthy Volunteers|
In this Phase II trial, 48 older adults with mild Alzheimer's disease will take either riluzole or a placebo. Riluzole is a medication (a tablet taken by mouth) with neuroprotective properties that affects glutamate, a nerve-cell messenger. It is used to slow down the progress of ALS but is not approved to treat Alzheimer's. Participants will undergo brain scans and other tests to gauge the drug's impact on the brain and cognitive functioning.
|Map Marker||City||State||Zip Code||Status||Primary Contact|
Geolocation is 40.7645239, -73.9624327
Ana Pereira, MD